Skip to main content
. Author manuscript; available in PMC: 2020 Nov 7.
Published in final edited form as: Heart Rhythm. 2020 Mar 4;17(7):1057–1065. doi: 10.1016/j.hrthm.2020.02.030

Figure 1.

Figure 1

Primary end point (composite of all-cause mortality and heart failure hospitalization) in ablated or drug-treated patients with atrial fibrillation and heart failure, stratified by Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF) trial eligibility criteria. The cumulative incidence in the overall cohort (A), in patients who would be potentially eligible for CASTLE-AF (B), in patients who failed to meet the inclusion criteria (C), and in patients who met at least one of the trial exclusion criteria (D). Drug-treated patients are the reference group in Cox proportional hazards regression analyses. All the curves and numbers were generated using propensity score weighting. CI = confidence interval.